Fort Washington Investment Advisors Inc. OH Sells 12,170 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Fort Washington Investment Advisors Inc. OH lowered its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 715,500 shares of the biotechnology company's stock after selling 12,170 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 0.38% of BioMarin Pharmaceutical worth $47,030,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in BMRN. Erste Asset Management GmbH purchased a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $48,527,000. Assenagon Asset Management S.A. grew its position in shares of BioMarin Pharmaceutical by 461.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after acquiring an additional 502,695 shares during the period. Vestal Point Capital LP purchased a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth $28,116,000. Clearline Capital LP bought a new position in BioMarin Pharmaceutical in the 3rd quarter worth $22,477,000. Finally, Dimensional Fund Advisors LP lifted its position in BioMarin Pharmaceutical by 38.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company's stock valued at $85,178,000 after purchasing an additional 289,953 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the sale, the executive vice president now owns 68,909 shares of the company's stock, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Trading Down 0.8 %

BMRN stock traded down $0.51 during mid-day trading on Wednesday, reaching $62.02. 1,554,836 shares of the stock traded hands, compared to its average volume of 1,716,487. BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The stock has a market capitalization of $11.82 billion, a PE ratio of 37.14, a PEG ratio of 0.54 and a beta of 0.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. The business has a 50-day moving average price of $65.32 and a two-hundred day moving average price of $74.02.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.23). The firm had revenue of $746.00 million during the quarter, compared to analysts' expectations of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The business's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. Equities research analysts expect that BioMarin Pharmaceutical Inc. will post 2.5 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on BMRN shares. Evercore ISI lowered their price objective on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. Raymond James reiterated an "outperform" rating and issued a $79.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, October 10th. Canaccord Genuity Group reduced their price objective on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating for the company in a research note on Wednesday, October 30th. Wedbush upgraded shares of BioMarin Pharmaceutical to a "strong-buy" rating in a research note on Monday, November 4th. Finally, Robert W. Baird cut their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating for the company in a research note on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $94.20.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.